SAN DIEGO and DEERFIELD, Ill., Nov. 11, 2013 /PRNewswire/ -- Orexigen® Therapeutics, Inc. (Nasdaq: OREX) and Takeda Pharmaceuticals U.S.A., Inc. (Takeda), today announced multiple Contrave® (naltrexone sustained release (SR)/bupropion SR) abstracts accepted for poster......
More...